UNO101
2 abstracts
Abstract
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.Org: Soroka - Clalit and Ben Gurion University Medical Center, Beer Sheva, Israel, Beyond Cancer, Rehovot, Israel,
Abstract
Effect of UNO101 on tumor microenvironment in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies..Org: Soroka - Clalit and Ben Gurion University Medical Center, Stanford University Medical Center, Stanford, CA, Beyond Cancer,